New interim analysis study findings presented for the first time at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab (BR) as a new treatment option for fit elderly patients with advanced Chronic Lymphocytic Leukaemia (CLL)
- IMF News - B-roll from International Monetary and Financial Committee meeting
- IMF News - "The world economy is facing a new and major test" - MD Presser
- IMF News - Spring Fiscal Monitor reports that global public debt is high and rising
- IMF News - Projections for global growth lowered to 2.8% this year - WEO
- IMF News - New B-roll from Spring Meetings week in Washington, D.C.
For European medical media: CLL10 Suggests Levact & Rituximab as New Treatment Option for Fit Elderly CLL Patients
Release Date: 09 Dec 2013
